The short version of preclinical models fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-12 and is reviewed periodically as new material appears.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
==== Stress management ==== Although psychological stress is recognized as a risk factor for type 2 diabetes, the effect of stress management interventions on disease progression are not established. A Cochrane review is under way to assess the effects of mindfulness‐based interventions for adults with type 2 diabetes.
Aminoacyl-tRNA synthetase enzymes consume ATP in the attachment tRNA to amino acids, forming aminoacyl-tRNA complexes. Aminoacyl transferase binds AMP-amino acid to tRNA. The coupling reaction proceeds in two steps: aa + ATP ⟶ aa-AMP + PPi aa-AMP + tRNA ⟶ aa-tRNA + AMP The amino acid is coupled to the penultimate nucleotide at the 3′-end of the tRNA (the A in the sequence CCA) via an ester bond (roll over in illustration). Transporting chemicals out of a cell against a gradient is often associated with ATP hydrolysis. Transport is mediated by ATP binding cassette transporters. The human genome encodes 48 ABC transporters, that are used for exporting drugs, lipids, and other compounds.
Pharmacodynamics (PD) is the core principle of quantifying the effects of antagonists by measuring the drug's efficacy and safety. PD emphasises the relationship between the dose and response of a certain drug, which can be illustrated using a dose-response curve. Efficacy is the maximal effect (Emax) that an agonist can produce. As a receptor antagonist does not affect receptors after binding, it is said to have zero efficacy. A competitive antagonist does not affect the Emax of the agonist. This is because the effect of an agonist can be maximized by adding the dose of the agonist as the action of the antagonist is reversible. The maximum effect of the agonist can be achieved by adding the concentration of the agonist. A non-competitive antagonist(or Allosteric antagonist) lowers the Emax of an agonist. The Emax of an agonist is inversely proportional to the concentration of the antagonist, which means a higher concentration of antagonist results in a lower Emax. The maximal efficacy of agonists is reduced as the inhibition cannot be reversed by adding the agonist concentration.
== Others == Endogenous Adrenomedullin Apelin Asprosin Bombesin Calcitonin Carnosine CART CLIP DSIP Enteroglucagon Formyl peptide GALP GIP GRP Integrin ligands collagens fibrinogen fibronectin laminins ICAM-1 ICAM-2 osteopontin VCAM-1 vitronectin Kininogens Motilin Natriuretic peptides ANP BNP CNP urodilatin Nesfatin-1 Neuromedin B Neuromedin N Neuromedin S Neuromedin U Obestatin Osteocalcin Resistin Secretin Thymopoietin Thymosins Thymulin Urotensin-II VGF Exogenous Lifitegrast (LFA-1 antagonist)
Sources: en.wikipedia.org
== Epidemiology == The HbS gene can be found in every ethnic group. The highest frequency of sickle cell disease is found in tropical regions, particularly sub-Saharan Africa, tribal regions of India, and the Middle East. About 80% of sickle cell disease cases are believed to occur in Sub-Saharan Africa. Migration of substantial populations from these high-prevalence areas to low-prevalence countries in Europe has dramatically increased in recent decades and in some European countries, sickle cell disease has now overtaken more familiar genetic conditions such as haemophilia and cystic fibrosis. In 2015, it resulted in about 114,800 deaths. Sickle cell disease occurs more commonly among people whose ancestors lived in tropical and subtropical sub-Saharan regions where malaria is or was common. Where malaria is common, carrying a single sickle cell allele (trait) confers a heterozygote advantage; humans with one of the two alleles of sickle cell disease show less severe symptoms when infected with malaria. This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. The parents each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
Miller (1992), professor of law at the University of Iowa Matthew Shum (1992), professor of economics at California Institute of Technology Victor Fleischer (1993), professor of law at University of California, Irvine Valerie Purdie Greenaway (1993), professor of psychology and first African-American to receive tenure in the sciences at Columbia University Michelle Hartman (1993), professor of Arabic and francophone literature at McGill University Soyoung Lee (1993), chief curator of the Harvard Art Museums Seth Rockman (1993), professor at Brown University, co-recipient of the 2010 Merle Curti Award David Rosen (1993), professor at Trinity College, Connecticut, recipient of the 2013 James Russell Lowell Prize David Eisenbach (1994), historian on media and politics; narrator, 10 Things You Don't Know About François Furstenberg (1994), historian at Johns Hopkins University Katerina Harvati (1994), professor of paleoanthropology at the University of Tübingen, identified the earliest known sample of the remains of modern humans outside Africa Ayanna Thompson (1994), professor of English at Arizona State University, president of the Shakespeare Association of America David H.
Phlebotomy is the process of making a puncture in a vein, usually in the arm or hand, with a cannula for the purpose of drawing blood. The procedure itself is known as a venipuncture, which is also used for intravenous therapy. A person who performs a phlebotomy is called a phlebotomist, although most doctors, nurses, and other technicians can also carry out a phlebotomy. In contrast, phlebectomy is the removal of a vein. Phlebotomies that are carried out in the treatment of some blood disorders are known as therapeutic phlebotomies. The average volume of whole blood drawn in a therapeutic phlebotomy to an adult is 1 unit (450–500 ml) weekly to once every several months, as needed.
Sources: en.wikipedia.org
The first stable human-animal chimeras to actually exist were first created by Shanghai Second Medical University scientists in 2003, the result of having fused human cells with rabbit eggs. In 2017 researchers led by the Salk Institute published in Cell experiments using CRISPR-Cas9 gene editing to aid in blastocyst complementation with pluripotent stem cells in various mammals. This included a human-pig chimera reported to have 0.001% human cells, with the remaining cells pig. The embryo consisted mostly pig cells and some human cells. Scientists stated that they hope to use this technology to address the shortage of donor organs. In 2021, a human-monkey chimera was created as a joint project between the Salk Institute in the US and Kunming University in China and published in the journal Cell. This involved injecting human stem cells into monkey embryos. The embryos were only allowed to grow for a few days, but the study demonstrated that some of these embryos still had human stem cells surviving at the end of the experiments. Because humans are more closely related to monkeys than other animals, it means there is more chance of the chimeric embryos surviving for longer periods so that organs can develop. The project has opened up possibilities into organ transplantation as well as ethical concerns particularly concerning human brain development in primates.
Wang, N.; He, Y.; Liu, S.; Makarcyzk, M. J.; Lei, G.; Chang, A.; Alexander, P. G.; Hao, T.; Padget, A. M.; De Pedro, N.; Menelaos, T.; Lin, H. (2022). "Engineering Osteoarthritic Cartilage Model". Science China Life Sciences. 65 (2): 309–327. doi:10.1007/s11427-021-1933-7. PMC 10077511. PMID 34109475. S2CID 235393377. Jogi, R.; Tager, M. J.; Perez, D.; Tsapekos, M. (2021). "Bovine Colostrum, Telomeres and Skin aging". Journal of Drugs in Dermatology. 20 (5): 538–545. doi:10.36849/JDD.5851. PMID 33938706. Shafa, M.; Walsh, T.; Panchalingam, K. M.; Richardson, T.; Menendez, L.; Tian, X.; Suresh Babu, S.; Dadgar, S.; Beller, J.; Yang, F.; Baghbaderani, B. A. (2019). "Long-term Stability and Differentiation Potential of Cryopreserved CGMP-compliant Human Induced Pluripotent Stem Cells". International Journal of Molecular Sciences. 21 (1): 108. doi:10.3390/ijms21010108. PMC 6982271. PMID 31877913. Samuel, P.; Tsapekos, M.; De Pedro, N.; Liu, A. G.; Casey Lippmeier, J.; Chen, S. (2022). "Ergothioneine Mitigates Telomere Shortening under Oxidative Stress Conditions". Journal of Dietary Supplements. 19 (2): 212–225. doi:10.1080/19390211.2020.1854919. PMID 33287595. S2CID 227953602. Mehkri, S.; Perez, Diego; Najarro, Pilar; Tsapekos, Menelaos; Bopanna, K. N. (July 2019). "Effect of Lutein (Lute-gen®) on Proliferation Rate and Telomere Length In Vitro and Possible Mechanism of Action". International Journal of Biology Research. 4 (3): 84–91. Phillippe, M.; Sawyer, M. R.; Edelson, P. K. (2019). "The Telomere Gestational Clock". American Journal of Obstetrics and Gynecology.
=== South America === Argentina banned kratom in 2017. Chile banned kratom in 2021. Brazil listed kratom as a New Psychoactive Substance (NPS) in 2020. It remains legal until it is included among prohibited substances.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.